Teijin Limited

Equities

3401

JP3544000007

Textiles & Leather Goods

Delayed Japan Exchange 08:14:56 2024-04-25 pm EDT 5-day change 1st Jan Change
1,494 JPY -1.39% Intraday chart for Teijin Limited +0.94% +11.97%

Teijin : Pharma Starts Operation of New R&D Center to Accelerate Material and Pharmaceutical Integrated Development

October 02, 2015 at 12:46 am EDT

Tokyo, Japan, October 2, 2015 --- Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced that it has opened the Technology Integrated Pharmaceutics Center to leverage the group's total resources for material and pharmaceuticals integrated development, such as a promising fibrin sheet offering high-performance hemostatic and tissue-sealing properties for surgical operations.

The Center's new two-story building will be equipped with Good Manufacturing Practice zones, manufacturing and testing equipment, and unique R&D facilities for pharmaceutical-material integration. The facility, measuring 2,300 square meters in floor space, will be located in the Pharmaceutical Products Research Laboratories of Teijin's Iwakuni Factory in western Japan at a cost of approximately two billion JPY (16.3 million USD). Construction of the center begun in October 2014.

Teijin Group is aiming at creating new health care business by overlapping the group's materials and health care domains under under the Transformation and Growth Strategies. As one such integrative undertaking, Teijin Pharma is developing KTF-374, an advanced sheet-type fibrin sealant offering high-performance hemostatic and tissue-sealing properties for surgical operations.

The Technology Integrated Pharmaceutics Center will consolidate systems for R&D functions for integrative products, as well as facilitate the manufacture of investigational drugs and the development of mass production processes for KTF-374.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 150 companies and around 16,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY786.2 billion (USD 6.6 billion) and total assets of JPY 823.7 billion (USD 6.9 billion) in the fiscal year ending March 31, 2015.

Press Contact
Corporate Communications
Teijin Limited
+81 3 3506 4055
pr@teijin.co.jp

Information in the press releases is current on the date of the announcement.
It is subject to change without prior notice.

Back to 2015 News

Back to Healthcare

Page Top

distributed by

© Publicnow - 2015
Teijin Swings to Fiscal Q1-Q3 Profit MT
Transcript : Teijin Limited, Q3 2024 Earnings Call, Feb 08, 2024
Teijin Limited Provides Dividend Guidance for the Full Year Ending March 31, 2024 CI
Teijin Limited Revises Earnings Guidance for the Year Ending March 31, 2024 CI
Garwood Medical Devices, LLC announced that it has received funding from Teijin Limited, Pegasus Tech Ventures, Inc. CI
Ascendis Pharma A/S Announces Strategic Partnership with Teijin Limited in Japan CI
Transcript : Teijin Limited, Q2 2024 Earnings Call, Nov 06, 2023
Teijin Limited Revises Earnings Guidance for the Year Ending March 31, 2024 CI
Japan stocks retreat from 33-year peak ahead of Fed policy decision RE
Japan stocks retreat from 33-year peak ahead of Fed policy decision RE
Tipcomposite Co.,Ltd. signed a share transfer agreement to acquire a 99.1% stake in GH Craft Ltd. from Teijin Limited CI
Teijin Limited Provides Dividend Guidance for the Full Year Ending March 31, 2024 CI
Teijin Limited Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024 CI
Teijin Limited Provides Dividend Guidance for the End of Second Quarter of Full Year Ending March 31, 2024 CI
Transcript : Teijin Limited, Q1 2024 Earnings Call, Aug 07, 2023
Teijin to Issue Restricted Stock as Remuneration MT
Teijin Limited Approves the Election of Noboru Yamanishi and Tamie Minami as Directors CI
Teijin Establishes New Subsidiary via Company Split MT
Teijin Announces Establishment of A Subsidiary by Company Split CI
Teijin Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Transcript : Teijin Limited, 2023 Earnings Call, May 11, 2023
Teijin Limited Announces Dividend for the Fourth Quarter of Fiscal Year Ended 2022 CI
Teijin Limited Provides Dividend Guidance for the Fiscal Year 2023 CI
Teijin Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Teijin Limited Provides Dividend Guidance for the Second Quarter of 2023 CI
Chart Teijin Limited
More charts
Teijin Limited is a diversified group organized around 5 areas of activity: - manufacturing and distribution of textile products and clothes (37.6% of net sales): textile fibers, polyesters, polymers, etc.; - production of synthetic fibers (35.5%): aramid, carbon and polyester fibers for industrial applications; - manufacturing of care and health products (17.8%): medicines (for the treatment of metabolic, cardiovascular, bone, joint and respiratory diseases), and home care equipments (home oxygen therapy equipments and positive pressure fans); - sale of IT products and services (6.9%); - other (2.2%). Net sales break down geographically as follows: Japan (58.6%), China (13.1%), Asia (6.9%), Americas (13.7%) and other (7.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
1,516 JPY
Average target price
1,340 JPY
Spread / Average Target
-11.58%
Consensus
  1. Stock Market
  2. Equities
  3. 3401 Stock
  4. News Teijin Limited
  5. Teijin : Pharma Starts Operation of New R&D Center to Accelerate Material and Pharmaceutical Integrated Development